JP5843416B2 - ステロイドホルモンを含むタブレット - Google Patents

ステロイドホルモンを含むタブレット Download PDF

Info

Publication number
JP5843416B2
JP5843416B2 JP2008503397A JP2008503397A JP5843416B2 JP 5843416 B2 JP5843416 B2 JP 5843416B2 JP 2008503397 A JP2008503397 A JP 2008503397A JP 2008503397 A JP2008503397 A JP 2008503397A JP 5843416 B2 JP5843416 B2 JP 5843416B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
steroid hormone
steroid
ment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008503397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534533A (ja
JP2008534533A5 (enExample
Inventor
マルクス・クルメ
アルベルト・ラードルマイアー
サーシャ・ゲネラール
ミヒャエル・ディットゲン
キース・ジェンセン
Original Assignee
エルテーエス ローマン テラピー−ジステーメ アーゲー
エルテーエス ローマン テラピー−ジステーメ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36998911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5843416(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エルテーエス ローマン テラピー−ジステーメ アーゲー, エルテーエス ローマン テラピー−ジステーメ アーゲー filed Critical エルテーエス ローマン テラピー−ジステーメ アーゲー
Publication of JP2008534533A publication Critical patent/JP2008534533A/ja
Publication of JP2008534533A5 publication Critical patent/JP2008534533A5/ja
Application granted granted Critical
Publication of JP5843416B2 publication Critical patent/JP5843416B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008503397A 2005-03-31 2006-03-15 ステロイドホルモンを含むタブレット Expired - Fee Related JP5843416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005015128.0 2005-03-31
DE102005015128A DE102005015128B4 (de) 2005-03-31 2005-03-31 Wafer enthaltend Steroidhormone
PCT/EP2006/002358 WO2006102990A2 (de) 2005-03-31 2006-03-15 Wafer enthaltend steroidhormone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013087238A Division JP2013155190A (ja) 2005-03-31 2013-04-18 ステロイドホルモンを含むタブレット

Publications (3)

Publication Number Publication Date
JP2008534533A JP2008534533A (ja) 2008-08-28
JP2008534533A5 JP2008534533A5 (enExample) 2009-04-09
JP5843416B2 true JP5843416B2 (ja) 2016-01-13

Family

ID=36998911

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008503397A Expired - Fee Related JP5843416B2 (ja) 2005-03-31 2006-03-15 ステロイドホルモンを含むタブレット
JP2013087238A Pending JP2013155190A (ja) 2005-03-31 2013-04-18 ステロイドホルモンを含むタブレット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013087238A Pending JP2013155190A (ja) 2005-03-31 2013-04-18 ステロイドホルモンを含むタブレット

Country Status (26)

Country Link
US (2) US9763960B2 (enExample)
EP (1) EP1863444B1 (enExample)
JP (2) JP5843416B2 (enExample)
KR (2) KR20140063740A (enExample)
CN (2) CN104983669B (enExample)
AR (1) AR054245A1 (enExample)
AU (1) AU2006228820B2 (enExample)
BR (1) BRPI0609601A2 (enExample)
CA (1) CA2598892C (enExample)
CR (1) CR9468A (enExample)
DE (1) DE102005015128B4 (enExample)
DO (1) DOP2006000070A (enExample)
EA (1) EA014183B1 (enExample)
GT (1) GT200600126A (enExample)
IL (1) IL186081A0 (enExample)
MX (1) MX2007012081A (enExample)
NO (1) NO20075404L (enExample)
NZ (1) NZ592882A (enExample)
PE (1) PE20061194A1 (enExample)
SG (1) SG179459A1 (enExample)
SV (1) SV2008002466A (enExample)
TW (1) TWI393576B (enExample)
UA (1) UA92011C2 (enExample)
UY (1) UY29441A1 (enExample)
WO (1) WO2006102990A2 (enExample)
ZA (1) ZA200706116B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
NZ586666A (en) * 2008-02-13 2012-04-27 Bayer Schering Pharma Ag Estradiol-containing drug delivery system
KR20100117603A (ko) * 2008-02-13 2010-11-03 바이엘 쉐링 파마 악티엔게젤샤프트 안정화 효과를 갖는 약물 전달 시스템
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
AU2012385956B2 (en) 2012-07-23 2017-03-30 Crayola, Llc Dissolvable films and methods of using the same
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
MX2020008147A (es) * 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4136162A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
AU2001273231A1 (en) * 2000-07-06 2002-01-21 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
JP2007500729A (ja) * 2003-07-31 2007-01-18 アイバックス コーポレイション 雄性及び雌性の性機能障害の治療方法
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze

Also Published As

Publication number Publication date
JP2013155190A (ja) 2013-08-15
EA200702102A1 (ru) 2008-04-28
WO2006102990A2 (de) 2006-10-05
TW200714299A (en) 2007-04-16
US9763960B2 (en) 2017-09-19
AU2006228820B2 (en) 2011-08-25
SV2008002466A (es) 2008-02-08
ZA200706116B (en) 2008-11-26
KR20140063740A (ko) 2014-05-27
EP1863444A2 (de) 2007-12-12
JP2008534533A (ja) 2008-08-28
US20060222708A1 (en) 2006-10-05
CN104983669A (zh) 2015-10-21
BRPI0609601A2 (pt) 2010-04-20
NZ592882A (en) 2012-12-21
KR20080002798A (ko) 2008-01-04
SG179459A1 (en) 2012-04-27
TWI393576B (zh) 2013-04-21
CN101132766A (zh) 2008-02-27
DE102005015128B4 (de) 2008-12-11
CN104983669B (zh) 2018-05-18
EP1863444B1 (de) 2015-12-09
PE20061194A1 (es) 2006-11-23
US20170348321A1 (en) 2017-12-07
GT200600126A (es) 2007-03-14
DE102005015128A1 (de) 2006-10-05
NO20075404L (no) 2007-12-20
AU2006228820A1 (en) 2006-10-05
MX2007012081A (es) 2007-11-21
WO2006102990A3 (de) 2007-03-22
IL186081A0 (en) 2008-01-20
KR101428625B1 (ko) 2014-08-13
UA92011C2 (ru) 2010-09-27
DOP2006000070A (es) 2007-08-15
AR054245A1 (es) 2007-06-13
EA014183B1 (ru) 2010-10-29
CR9468A (es) 2008-01-21
CA2598892C (en) 2014-10-14
UY29441A1 (es) 2006-10-31
CA2598892A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP2013155190A (ja) ステロイドホルモンを含むタブレット
KR102735893B1 (ko) 에스테트롤 성분을 함유하는 구강분해성 투여 단위
KR102158948B1 (ko) 약물 전달 시스템
JPH11513393A (ja) 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
JP2001524958A (ja) 新規な液晶をベースとする生物接着性薬剤送出系
TW200808382A (en) Film-shaped drug forms for use in the oral cavity (wafers)
EA018330B1 (ru) Система доставки лекарственного средства со стабилизирующим эффектом
HK1116055A (en) Tablet containing steroid hormones
KR102862769B1 (ko) 코르티코스테로이드의 점막부착성 제약 조성물
US20120282340A1 (en) Drug delivery system
NZ618535B2 (en) Drug delivery system
JPH08104621A (ja) ガム型徐放製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130418

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130514

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130607

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151117

R150 Certificate of patent or registration of utility model

Ref document number: 5843416

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees